Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 214,233 shares of the medical equipment provider’s stock after acquiring an additional 16,262 shares during the period. Handelsbanken Fonder AB’s holdings in Hologic were worth $15,444,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. General Partner Inc. bought a new stake in Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment increased its holdings in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC raised its position in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Raymond James restated an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.88% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $64.47 on Friday. The firm has a market capitalization of $14.47 billion, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 2.13 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a one year low of $62.69 and a one year high of $84.67. The stock’s fifty day moving average is $69.91 and its 200-day moving average is $76.61.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.